Role of the DNA base excision repair protein, APE1 in cisplatin, oxaliplatin, or carboplatin induced sensory neuropathy

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Kelley, Mark R ^a   Jiang, Yanlin ^a   Guo, Chunlu ^a   Reed, April ^a   Meng, Hongdi ^a   Vasko, Michael R ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYGUANINE; CAPSAICIN; CARBOPLATIN; CISPLATIN; DNA BASE; DNA BASE EXCISION REPAIR PROTEIN; E 3330; HISTONE H2AX; OXALIPLATIN; REACTIVE OXYGEN METABOLITE; REDOX EFFECTOR FACTOR 1; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; PLATINUM COMPLEX;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DNA ADDUCT; DNA BASE COMPOSITION; DNA DAMAGE; DNA REPAIR; IN VIVO STUDY; MALE; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SENSORY NERVE CELL; VASODILATATION; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM;

ANIMALS; CARBOPLATIN; CELLS, CULTURED; CISPLATIN; DNA DAMAGE; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; MALE; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; SENSORY RECEPTOR CELLS;

EID: 84906979415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106485     Document Type: Article

References (78)

1. Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55: 2303-l2306
2. Go RS, Adjei AA (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17: 409-422
3. Todd RC, Lippard SJ (2009) Inhibition of transcription by platinum antitumor compounds. Metallomics 1: 280-291
4. Cavaletti G, Marmiroli P (2010) Chemotherapy-induced peripheral neurotoxicity. Nat Rev Neurol 6: 657-666
5. McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8: 10-16
6. Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, et al. (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10: 795-803
7. Duarte D, Vasko M (2012) The Role of DNA Damage and Repair in Neurotoxicity Caused by Cancer Therapies. In: Kelley M, editor. DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Academic Press/Elsevier. pp.283-295
8. Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13: 27-46
9. Schulze C, McGowan M, Jordt SE, Ehrlich BE (2011) Prolonged oxaliplatin exposure alters intracellular calcium signaling: a new mechanism to explain oxaliplatin-associated peripheral neuropathy. Clin Colorectal Cancer 10: 126-133
10. Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29: 21-33
11. Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005) Oxaliplatininduced neurotoxicity and the development of neuropathy. Muscle Nerve 32: 51-60
12. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatininduced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29: 387-392
13. Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9: 1053-1071
14. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, et al. (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20: 1767-1774
15. Heinzlef O, Lotz JP, Roullet E (1998) Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 64: 667-669
16. Screnci D, McKeage MJ (1999) Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J Inorg Biochem 77: 105-110
17. Amptoulach S, Tsavaris N (2011) Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract 2011: 843019
18. Chvalova K, Brabec V, Kasparkova J (2007) Mechanism of the formation of DNA-protein cross-links by antitumor cisplatin. Nucleic Acids Res 35: 1812-1821
19. Meijer C, de Vries EG, Marmiroli P, Tredici G, Frattola L, et al. (1999) Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. NeuroToxicology 20: 883-887
20. Ta LE, Espeset L, Podratz J, Windebank AJ (2006) Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. NeuroToxicology 27: 992-1002
21. Fischer SJ, McDonald ES, Gross L, Windebank AJ (2001) Alterations in cell cycle regulation underlie cisplatin induced apoptosis of dorsal root ganglion neurons in vivo. Neurobiol Dis 8: 1027-1035
22. McDonald ES, Randon KR, Knight A, Windebank AJ (2005) Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 18: 305-313
23. Gill JS, Windebank AJ (1998) Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101: 2842-2850
24. Jiang Y, Guo C, Vasko MR, Kelley MR (2008) Implications of Apurinic/ Apyrimidinic Endonuclease in Reactive Oxygen Signaling Response after Cisplatin Treatment of Dorsal Root Ganglion Neurons. Cancer Res 68: 6425-6434
25. Verdu E, Vilches JJ, Rodriguez FJ, Ceballos D, Valero A, et al. (1999) Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 22: 329-340
26. Blisard KS, Rogers SL, Alexander S, Harrington DA (1992) Neurotoxic effects of platinum compounds in cultured dorsal root ganglion cells. J Exp Pathol 6: 65-74
27. Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon M-S, et al. (2007) Repair Capacity for Platinum-DNA Adducts Determines the Severity of Cisplatin-Induced Peripheral Neuropathy. J Neurosci 27: 9451-9457
28. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G (1998) Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol 9: 443-447
29. Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, et al. (1997) Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 18: 559-571
30. Rybak LP, Ravi R, Somani SM (1995) Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol 26: 293-300
31. Feghali JG, Liu W, Van De Water TR (2001) L-n-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 111: 1147-1155
32. van den Berg JH, Beijnen JH, Balm AJ, Schellens JH (2006) Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev
33. Haihong Z, Takatsugu M, Jaime C-T, Liwen L, Akihiro N, et al. (2007) Targeting human 8-oxoguanine DNA glycosylase (hOGG1) to mitochondria enhances cisplatin cytotoxicity in hepatoma cells. Carcinogenesis 28: 1629-1629
34. Kim YJ, Wilson DM 3rd (2011) Overview of Base Excision Repair Biochemistry. Curr Mol Pharmacol
35. Fung H, Demple B (2005) A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol Cell 17: 463-470
36. Fishel ML, Vasko MR, Kelley MR (2007) DNA repair in neurons: so if they don't divide what's to repair? Mutat Res 614: 24-36
37. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR (2009) The Many Functions of APE1/Ref-1: Not Only a DNA Repair Enzyme. Antioxid Redox Signal 11: 601-620
38. Vascotto C, Fishel M (2012) Blockade of Base Excision Repair: inhibition of small lesions results in big consequences to cancer cells. In: Kelley M, editor. DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Academic Press/Elsevier. pp.29-47
39. Kelley M, Georgiadis M, Fishel M (2012) APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1. Current Molecular Pharmacology 5: 36-53
40. Fishel ML, Kelley MR (2007) The DNA base excision repair protein Ape1/Ref- 1 as a therapeutic and chemopreventive target. Mol Aspects Med 28: 375-395
41. Jiang Y, Sandusky GE, Kelley MR, Fishel ML (2010) Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Investigation 28: 885-895
42. Bapat A, Fishel ML, Kelley MR (2009) Going ape as an approach to cancer therapeutics. Antioxid Redox Signal 11: 651-668
43. Vasko MR, Guo C, Thompson EL, Kelley MR (2011) The repair function of the multifunctional DNA repair/redox protein APE1 is neuroprotective after ionizing radiation. DNA Repair (Amst) 10: 942-952
44. Jiang Y, Guo C, Fishel ML, Wang ZY, Vasko MR, et al. (2009) Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair (Amst) 8: 1273-1282.
45. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, et al. (2014) Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 32: 1941- 1967
46. Earley JN, Turchi JJ (2011) Interrogation of Nucleotide Excision Repair Capacity: Impact on Platinum-Based Cancer Therapy. Antioxid Redox Signal
47. Ferroni P, Della-Morte D, Palmirotta R, McClendon M, Testa G, et al. (2011) Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention. Rejuvenation Res 14: 293-308
48. Kinoshita A, Wanibuchi H, Imaoka S, Ogawa M, Masuda C, et al. (2002) Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: Association with expression profiles of p21(WAF1/Cip1), cyclin D1 and Ogg1. Carcinogenesis 23: 341-349
49. Kim HJ, Lee JH, Kim SJ, Oh GS, Moon HD, et al. (2010) Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. J Neurosci 30: 3933-3946
50. Pak JH, Choi WH, Lee HM, Joo WD, Kim JH, et al. (2011) Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest 29: 21-28
51. Carozzi VA, Marmiroli P, Cavaletti G (2010) The role of oxidative stress and anti-oxidant treatment in platinum-induced peripheral neurotoxicity. Curr Cancer Drug Targets 10: 670-682
52. Richardson JD, Vasko MR (2002) Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 302: 839-845
53. Gracias N, Cummins T, Kelley M, Basile D, Iqbal T, et al. (2011) Vasodilatation in the rat dorsal hindpaw induced by activation of sensory neurons is reduced by Paclitaxel. NeuroToxicology 32: 140-149
54. Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320
55. David SS, O'Shea VL, Kundu S (2007) Base-excision repair of oxidative DNA damage. Nature 447: 941-950
56. Turchi J, Patrick S (2012) Targeting the Nucleotide Excision Repair Pathway for Therapeutic Applications. In: Kelley M, editor. DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications: Elsevier. pp.109-115
57. Holzer P (1988) Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 24: 739-768
58. Luo M, Zhang J, He H, Su D, Chen Q, et al. (2012) Characterization of the redox activity and disulfide bond formation in apurinic/apyrimidinic endonuclease. Biochemistry 51: 695-705
59. Georgiadis M, Luo M, Zhang J, Basavarajappa H, Mahalingan K, et al. (2012) An uncharged amide derivative of E3330 inhibits the redox but not the DNAbinding activity of APE1. Bioorganic Medicinal Chemistry
60. Su D, Delaplane S, Luo M, Rempel DL, Vu B, et al. (2010) Interactions of Apurinic/Apyrimidinic Endonuclease with a Redox Inhibitor: Evidence for an Alternate Conformation of the Enzyme. Biochemistry
61. Zhang J, Luo M, Marasco D, Logsdon D, LaFavers KA, et al. (2013) Inhibition of apurinic/apyrimidinic endonuclease I's redox activity revisited. Biochemistry 52: 2955-2966
62. Zheng H, Xiao WH, Bennett GJ (2011) Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Experimental Neurology 232: 154-161
63. Boyette-Davis J, Xin W, Zhang H, Dougherty PM (2011) Intraepidermal nerve fiber loss corresponds to the development of Taxol-induced hyperalgesia and can be prevented by treatment with minocycline. PAIN 152: 308-313
64. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, et al. (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25: 94-102
65. Liu C-C, Lu N, Cui Y, Yang T, Zhao Z-Q, et al. (2010) Prevention of Paclitaxelinduced allodynia by Minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Molecular Pain 6: 76
66. Englander EW (2013) DNA damage response in peripheral nervous system: Coping with cancer therapy-induced DNA lesions. DNA Repair 12: 685-690
67. El-Khamisy SF, Caldecott KW (2007) DNA single-strand break repair and spinocerebellar ataxia with axonal neuropathy-1. Neuroscience 145: 1260-1266
68. Kothandapani A, Sawant A, Dangeti VSMN, Sobol RW, Patrick SM (2013) Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Research
69. Nyland RL, Luo M, Kelley MR, Borch RF (2010) Design and Synthesis of Novel Quinone Inhibitors Targeted to the Redox Function of Apurinic/Apyrimidinic Endonuclease 1/Redox Enhancing Factor-1 (Ape1/Ref-1). J Med Chem 53: 1200-1210
70. Fishel M, Jiang Y, Rajeshkumar N, Sinn A, He Y, et al. (2011) Impact of APE1/ Ref-1 Redox Inhibition on Pancreatic Tumor Growth. Molecular Cancer Therapeutics 10: 1698-1708
71. Vasko MR, Guo C, Kelley MR (2005) The multifunctional DNA repair/redox enzyme Ape1/Ref-1 promotes survival of neurons after oxidative stress. DNA Repair (Amst) 4: 367-379
72. Bapat A, Glass LS, Luo M, Fishel ML, Long EC, et al. (2010) Novel smallmolecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther 334: 988-998
73. Wang D, Luo M, Kelley MR (2004) Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 3: 679-686
74. Luo M, Kelley MR (2004) Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 24: 2127-2134
75. Sultana R, McNeill DR, Abbotts R, Mohammed MZ, Zdzienicka MZ, et al. (2012) Synthetic lethal targeting of DNA double-strand break repair deficient cells by human apurinic/apyrimidinic endonuclease inhibitors. International Journal of Cancer 131: 2433-2444
76. Mohammed MZ, Vyjayanti VN, Laughton CA, Dekker LV, Fischer PM, et al. (2011) Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer 104: 653-663
77. Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, et al. (2005) Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res 33: 4711-4724
78. Rendell MS, Finnegan MF, Healy JC, Lind A, Milliken BK, et al. (1998) The relationship of laser-Doppler skin blood flow measurements to the cutaneous microvascular anatomy. Microvasc Res 55: 3-13.